Sandoz launches generic version of key anti-depressant Cipralex® in several European countries

Holzkirchen, June 4, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex®.

The Sandoz product, which is available in all strengths approved for the reference product (5mg, 10mg, 15mg and 20mg), was launched initially in countries including Belgium, France, Germany, Italy, Sweden and Switzerland.

Nick Haggar, Head of Sandoz Western Europe, Middle East and Africa, said: “Sandoz is already a regional …

/by

Sandoz launches AirFluSal® Forspiro® in South Korea

Seoul, May 14 2014 – Sandoz Korea announces that it is launching today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

​The product was first approved in Denmark in December, 2013 with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania, Bulgaria and South Korea.

“We are pleased to launch AirFluSal® Forspiro® in South Korea. This is a milestone in our strategy of bringing our world class innovative inhaler to patients in Korea,” said Sujun Park, Country Head of …

/by

Court supports access to Sandoz’s innovative respiratory device in Norway

We are pleased that a court in Norway has denied GSK’s request to restrict access to Sandoz’s AirFluSal® Forspiro® in Norway. AirFluSal® Forspiro® provides patients with asthma and/or COPD with an award-winning innovative device for delivering the proven combination of salmeterol (a long-acting inhaled ß2-agonist) and fluticasone (an inhaled corticosteroid). We look forward to continuing to provide patients access to this important device. The decision is still subject to appeal.

About Sandoz

Sandoz, the generic pharmaceuticals division of Novartis, is a global …

/by

Sandoz recognizes World Asthma Day 2014

Today Sandoz recognizes World Asthma Day. World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) with the goal of improving asthma awareness and care around the world. This year’s theme is, “It’s time to control asthma.”

A chronic, inflammatory lung disease, asthma is currently the most common non-communicable disease amongst children worldwide. GINA estimates that there are 300 million sufferers worldwide and there may be an additional 100 million people living with asthma by 2025.

Asthma is characterized by airway obstruction which results in …

/by

Sandoz launches generic version of Differin® Gel, 0.3%

Princeton, New Jersey, April 28, 2014 – Sandoz today announced the US market introduction of its adapalene 0.3% gel, a generic version of Galderma Laboratories’ Differin® Gel, 0.3%.

Adapalene gel is a retinoid, indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Acne vulgaris is a condition that affects nearly 85% of the US population at some point in their life.1

“Sandoz is proud to market a high-quality, affordable generic version of this important topical therapy,” said Peter Goldschmidt, President of Sandoz …

/by

Sandoz launches generic version of Differin® Gel, 0.3%

Princeton, New Jersey, April 28, 2014 – Sandoz today announced the US market introduction of its adapalene 0.3% gel, a generic version of Galderma Laboratories’ Differin® Gel, 0.3%.

Adapalene gel is a retinoid, indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Acne vulgaris is a condition that affects nearly 85% of the US population at some point in their life.1

“Sandoz is proud to market a high-quality, affordable generic version of this important topical therapy,” said Peter Goldschmidt, President of Sandoz …

/by

Sandoz achieves important milestones on Phase III trials for key biosimilars programs

April 28, 2014 – Sandoz continues to advance its industry-leading biosimilars pipeline that currently has six molecules in the Phase III clinical trial/filing prep phase.

As part of the Novartis Q1 announcements, Sandoz announced the following biosimilar development milestones:

  • Sandoz completed the patient enrollment for its Phase III trial with biosimilar etanercept (Amgen’s Enbrel®). The global clinical trial seeks to confirm biosimilarity with regard to safety, efficacy and immunogenicity of the Sandoz product versus Enbrel in patients with moderate to …
/by

Novartis announces Q1 2014 results

Basel, April 24, 2014 – Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolio

/by

Novartis announces Q1 2014 results

Basel, April 24, 2014 – Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolio

/by

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics

  • Acquires GSK oncology products, strengthening Novartis’ leading Oncology business with novel therapies and becomes GSK’s preferred commercialization partner for its oncology pipeline
  • Combines Novartis OTC with GSK’s consumer business in a joint venture, creating a world-leading consumer healthcare business and maintaining Novartis’ presence in in this sector
  • Divests Vaccines business (excluding flu) to GSK, creating a global leader in vaccines
  • In a separate transaction, divests Novartis Animal Health to Lilly

Transactions improve Novartis’ …

/by